Log In
BCIQ
Print this Print this
 

calaspargase pegol (EZN-2285)

  Manage Alerts
Collapse Summary General Information
Company Shire plc
DescriptionPegylated L-asparaginase
Molecular Target L-asparaginase
Mechanism of ActionEnzyme replacement therapy
Therapeutic ModalityBiologic: Enzyme
Latest Stage of DevelopmentPhase II
Standard IndicationAcute lymphoblastic leukemia (ALL)
Indication DetailsTreat acute lymphoblastic leukemia (ALL)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$900.0M

$900.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

05/12/2015

$900.0M

$900.0M

0

Get a free BioCentury trial today